Filing Flows › Biocryst Pharmaceuticals (BCRX) › Net income
Biocryst Pharmaceuticals (BCRX) net income by quarter
Biocryst Pharmaceuticals' net income was $37.9M in Q3 2026 (third quarter 2026), -52% from Q2 2026. Over the last 6 quarters it ranged from $32K (Q1 2025) to $246M (Q4 2025).
| Quarter | Net income | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $37.9M | -52% | +194% |
| Q2 2026 | $78.4M | -68% | 15× |
| Q4 2025 | $246M | 19× | — |
| Q3 2025 | $12.9M | +154% | — |
| Q2 2025 | $5.1M | 159× | — |
| Q1 2025 | $32K | — | — |
Q3 2026 at a glance
Biocryst Pharmaceuticals, Q3 2026: revenue $180M (+13% year over year), operating margin 29.6%, net earnings $37.9M, operating cash flow $33.0M. The chart follows the revenue to costs, profit and cash.
Questions
What is Biocryst Pharmaceuticals' net income?
Biocryst Pharmaceuticals' net income was $37.9M in Q3 2026 (third quarter 2026), -52% from Q2 2026.
How has Biocryst Pharmaceuticals' net income changed?
Over the last 6 quarters it ranged from $32K (Q1 2025) to $246M (Q4 2025).
Q3 2026 results → · How Biocryst Pharmaceuticals makes money →